Senior management

Gunilla Osswald
Gunilla Osswald
Chief Executive Officer since 2014

Gunilla Osswald has extensive experience in drug development (30 years) and has successfully brought projects from preclinical development all the way to regulatory approval and market introduction. She has also successfully managed in- and outlicensing of drug projects. Osswald was for many years active in leading positions at AstraZeneca including Vice President responsible for developing AstraZeneca’s product portfolio in neurodegenerative diseases.

Born: 1961
Education: Pharmacist and Doctor in biopharmacy and pharmacokinetics at Uppsala University.
Other current assignments: Gunilla Osswald is board member of PledPharma AB (publ) and SpineMedical AB and deputy board member of LPB Sweden AB and LPB Sweden Holding AB.
Prior assignments (past five years): During the past five years Gunilla Osswald has been board member of SP Process Development AB and SpineMedical Sverige AB.
Holdings in the Company: Gunilla Osswald owns 12,800 B-shares in the Company. She has also acquired 5,818 call options from the Main Shareholders. The options entitle to the acquisition of 87,270 B-shares in the Company.

Jan Mattsson
Jan Mattsson
Chief Financial Officer since 2017

Jan Mattsson has an MBA and has experience as CFO in listed as well as unlisted companies. Mattsson has been CFO in Sefina Finance AB, Allenex AB, Argnor Wireless Ventures AB, Logitall AB and Investment Kinnevik AB, among others.

Born: 1960
Education: Master of Business Administration, University of Örebro, 1984.
Other current assignments: Jan Mattsson is CEO and member of the board of Almsäter Interim Management AB.
Prior assignments (past five years): During the past five years Jan Mattsson has been member of the board of Sefina Finance AB, Sefina Svensk Pantbelåning AB and Humidus AB.
Holdings in the Company: Jan Mattson owns, privately and through Almsäter Interim Managemant AB, a total of 15,000 B-shares in the Company. Jan Mattsson has also acquired 1,818 call options from the Main Shareholders. The options entitle to the acquisition of 27,270 B-shares in the Company.

Christina Astrén Eriksson
Christina Astrén Eriksson
Communications Director since 2017

Christina Astrén Eriksson has long experience of communication issues in pharma companies, as interim responsible for communications at Orexo, and as Communications Director at Pfizer, Astra Zeneca, Wyeth and Pharmacia. She is active in BioArctic as a consultant

Born: 1959
Education: Degree in journalism, Stockholm University, 1984; Diploma from IHR (Institutet för Högre Kommunikations- och Reklamutbildning), Stockholm University, 1988.
Other current assignments: Christina Astrén Eriksson is CEO and chairman of the board of C Astrén AB, board member of Lötsberga kultur- och museistiftelse, Lötsberga AB and deputy board member of Lötsberga Förvaltning AB.
Holdings in the Company: Christina Astrén Eriksson owns, through C Astrén AB, 25,000 B-shares in the Company.

Hans Basun
Hans Basun
Chief Medical Officer since 2007

Hans Basun has a background as Senior Consultant at Huddinge University Hospital and Professor at Uppsala University Hospital. Hans Basun has been active in the pharma industry for 20 years in positions at Astra Arcus, AstraZeneca and now BioArctic.

Born: 1949
Education: Medical degree and residency in psychiatry and geriatrics, Associate Professor at Karolinska Institutet and Adjunct Professor at Uppsala University.
Other current assignments: Hans Basun is a deputy board member of SpineMedical AB.
Holdings in the Company: Hans Basun owns 20,823 B-shares in the Company. He has also acquired 1,818 call options from the Main Shareholders. The options entitle to the acquisition of 27,270 B-shares in the Company.

Johanna Fälting
Johanna Fälting
Head of the Department for Immunology and Pharmacology since 2012

Johanna Fälting has a PhD in Physiology and 15 years of experience of neuroscience/pharmacology, translational science and development in the global pharma and biotech industry.

Born: 1972
Education: PhD in Physiology, Stockholm University 2001; Licentiate degree in physiology, Stockholm University 1997; Master’s degree in biology, Stockholm University, 1995.
Other current assignments: Johanna Fälting is deputy board member of Biozoul AB.
Holdings in the Company: Johanna Fälting owns 10,000 B-shares in the Company. Johanna Fälting has also acquired 1,818 call options from the Main Shareholders. The options entitle to the acquisition of 27,270 B-shares in the Company.

Pär Gellerfors
Pär Gellerfors
Senior Vice President Business Strategy since 2014

Pär Gellerfors is together with Lars Lannfelt the founder of BioArctic. Gellerfors is Associate Professor of Biochemistry at Stockholm University. He is also co-founder of HemeBiotech/Zymenex A/S and has held several board memberships. Gellerfors is employed by the Company and responsible for business strategy. He is co-opted member of the senior management team. During 2003-2014 he was the CEO of BioArctic.

Born: 1947
Education: Bachelor in chemistry at Stockholm University 1967; PhD in chemistry at Stockholm University 1977; Associate Professor of Biochemistry at Stockholm University 1983.
Other current assignments: Pär Gellerfors is CEO and board member of Swenora Biotech AB, board member of BioArctic AB, Ackelsta AB, LPB Sweden AB and LPB Sweden Holding AB and deputy board member of Otwomed AB.
Prior assignments (past five years): During the past five years Pär Gellerfors has been CEO of BioArctic AB, CEO and board member of GPM Medical AB, SpineMedical Sverige AB and SpineMedical AB, board member of Hogholmen Förvaltning AB, Hogholmen AB and deputy board member of MILIDA AB.
Holdings in the Company: Pär Gellerfors owns, through the wholly-owned company Ackelsta AB, a total of 5,759,998 A-shares and 15,232,989 B-shares in the Company.

Mats Holmquist
Mats Holmquist
Responsible for Quality Assurance since 2008

Mats Holmquist is Doctor of Science biochemistry, Master of Engineering chemical engineering and has more than 20 years of leadership competence from roles in the academy and the international biotech and pharma industries with Gyros AB and AstraZeneca. He received the title of Associate Professor in Biochemistry at KTH Royal Institute of Technology in 2000.

Born: 1967
Education: Master of Engineering chemical engineering KTH Royal Institute of Technology 1990, Doctor of Science biochemistry KTH Royal Institute of Technology 1995, Associate Professor in Biochemistry, KTH Royal Institute of Technology 2000.
Holdings in the Company: Mats Holmquist has acquired 1,818 call options from the Main Shareholders. The options entitle to the acquisition of 27,270 B-shares in the Company.

Mikael Moge
Mikael Moge
Head of the Department for Biochemistry and Molecular Biology since 2012

Mikael Moge has previously been section manager at process R&D at AstraZeneca and has 20 years of experience from drug development and 15 years of experience as research and development manager within process development and GMP manufacturing.

Born: 1967
Education: Master of Engineering chemical engineering KTH Royal Institute of Technology, Doctor of Science organic chemistry KTH Royal Institute of Technology.
Holdings in the Company: Mikael Moge has acquired 455 call options from the Main Shareholders. The options entitle to the acquisition of 6,825 B-shares in the Company.

Christer Möller
Christer Möller
Chief Scientific Officer since 2006

Christer Möller has a comprehensive academic experience, having pursued research projects concerning growth factors and preclinical research in diabetes. He also has close to 20 years of experience from smaller biotech/pharma companies, from a leading position in Zymenex A/S developing protein drugs from idea to clinical trials, among other things.

Born: 1959
Education: B. Sc in Biology Stockholm University, 1983; PhD in Medical Science, Karolinska Institutet, 1992.
Holdings in the Company: Christer Möller owns 16,500 B-shares in the Company. Christer Möller has also acquired 1,818 call options from the Main Shareholders. The options entitle to the acquisition of 27,270 B-shares in the Company.

Holdings in BioArctic AB as of October 18, 2017